DOCSLIB.ORG

Genome-Wide Association Study Finds New Loci Affecting N-Glycosylation of Human Blood Plasma Proteins

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Genome-Wide Association Study Finds New Loci Affecting N-Glycosylation of Human Blood Plasma Proteins Genome-wide association study finds new loci affecting N-glycosylation of human blood plasma proteins Sodbo Zh. Sharapov1,2, Yakov A. Tsepilov1,2, Lucija Klaric3,4, Massimo Mangino5,6, Gaurav Thareja7, Alexandra S. Shadrina2, Mirna Simurina8, Concetta Dagostino9, Julia Dmitrieva10, Marija Vilaj4, FranoVuckovic4, Tamara Pavic8, Jerko Stambuk4, Irena Trbojevic-Akmacic4, Jasminka Kristic4, Jelena Simunovic4, Ana Momcilovic4, Harry Campbell11,12, Margaret Doherty13,14, Malcolm G Dunlop12, Susan M Farrington12, Maja Pucic-Bakovic4, Christian Gieger15, Massimo Allegri16, Edouard Louis17, Michel Georges10, Karsten Suhre7, Tim Spector5, Frances MK Williams5 1Institute of Cytology and Genetics SB RAS, Prospekt Lavrentyeva 10, Novosibirsk, 630090, Russia 2Novosibirsk State University, 1, Pirogova str., Novosibirsk, 630090, Russia 3MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XU, UK 4Genos Glycoscience Research Laboratory, Borongajska cesta 83h, 10000 Zagreb, Croatia 5Department of Twin Research and Genetic Epidemiology, School of Life Course Sciences, King’s College London, St Thomas’ Campus, Lambeth Palace Road, London, SE1 7EH, UK 6NIHR Biomedical Research Centre at Guy’s and St Thomas’ Foundation Trust, London SE1 9RT, UK. 7Department of Physiology and Biophysics, Weill Cornell Medicine-Qatar, Education City, PO 24144 Doha, Qatar 8Faculty of Pharmacy and Biochemistry, University of Zagreb, Ante Kovacica 1, 10 000 Zagreb, Croatia 9Department of Medicine and Surgery, University of Parma, Via Gramsci 14, 43126 Parma, Italy 10Unit of Animal Genomics, WELBIO, GIGA-R & Faculty of Veterinary Medicine, University of Liège (B34), 1 Avenue de l’Hôpital, Liège 4000, Belgium 11Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh EH8 9AG, UK 12Colon Cancer Genetics Group, MRC Human Genetics Unit, MRC Institute of Genetics & Molecular Medicine, Western General Hospital, The University of Edinburgh, Edinburgh EH4 2XU, UK 13Institute of Technology Sligo, Department of Life Sciences, Sligo, Ireland 14National Institute for Bioprocessing Research & Training, Dublin, Ireland 15Institute of Epidemiology II, Research Unit of Molecular Epidemiology, Helmholtz Centre Munich, German Research Center for Environmental Health, Ingolstädter Landstr. 1, D-85764, Neuherberg, Germany 16Pain Therapy Department Policlinico Monza Hospital, 20090 Monza, Italy 17CHU-Liège and Unit of Gastroenterology, GIGA-R & Faculty of Medicine, University of Liège, 1 Avenue de l’Hôpital, Liège 4000, Belgium 18PolyOmica, Het Vlaggeschip 61, 5237 PA 's-Hertogenbosch, The Netherlands Gordan Lauc4,8,*, Yurii Aulchenko1,2,18,* * These authors jointly supervised this work and contributed equally. Correspondence and requests for materials should be addressed to YA (email: [email protected], Tel: +7 (383) 363-49-63*1228, Fax: +7(383) 333-12-78) Glycosylation – covalent attachment of carbohydrates (glycans) to a substrate - is a common and structurally diverse cotranslational and posttranslational modification of proteins. Glycans influence the physical properties of proteins (solubility, conformation, folding, stability, trafficking, etc.) 1–3 as well as their biological functions including protein-protein, cell-cell, cell-matrix, and host-pathogen interactions 1,2,4,5. Alteration in glycosylation is observed in a number of human diseases such as type 1 and 2 diabetes 6, rheumatoid arthritis 7, Parkinson's disease 8 and cancer 9–11. Glycans are considered potential therapeutic targets 12 and biomarkers for early diagnosis and disease prognosis 13–16, making glycobiology a promising field for future clinical applications. Defining the genetic factors underlying glycosylation will potientially provide novel approaches to diagnostic and pharmaceutical applications. Genome-wide association studies (GWAS) provide important tools because of their hypothesis-free search of genes involved in regulation of glycosylation. Here we present a genetic study of the human blood plasma proteins N-glycosylation measured by Ultra Performance Liquid Chromatography (UPLC) technology in up to 3,811 people. We studied association between 8.5 million genetic polymorphisms on human autosomes and 113 relative abundances of N-glycan structures. We discovered and replicated twelve associated loci, seven of which were new. To prioritize potentially causal genes in the found loci we performed an extensive in silico functional study including analysis of eQTL effects, tissue/cell type expression enrichment analyses and gene-set enrichment analysis. The majority of loci contained genes that encode enzymes directly involved in glycosylation (FUT3/FUT6, FUT8, B3GAT1, ST6GAL1, B4GALT1, ST3GAL4, MGAT3, and MGAT5) and a known regulator of plasma protein fucosylation (HNF1A). However, we also found loci that could reflect other, more complex aspects of glycosylation process. Functional genomic annotation suggested the role of several genes including DERL3 (plays role in the degradation for misfolded luminal glycoproteins), CHCHD10 (encodes a mitochondrial protein that is enriched at cristae junctions in the intermembrane space), TMEM121, IGH (encodes immunoglobulin heavy chains), and IKZF1 (considered an important regulator of lymphocyte differentiation). These genes can be considered candidates for future experimental research. Additionally, we demonstrated a clear overlap in genetic control of glycosylation of plasma proteins and immunoglobulin G 18,19, leading is to future studies that will distinguish global, cell-, tissue-, and protein-specific pathways of protein glycosylation. Acknowledgements This work was supported by the European Community’s Seventh Framework Programme funded project PainOmics (Grant agreement # 602736), by the European Structural and Investment Funds IRI grant (#KK.01.2.1.01.0003) and Croatian National Centre of Research Excellence in Personalized Healthcare grant (#KK.01.1.1.01.0010). The work of ASh was supported by the Russian Ministry of Science and Education under the 5-100 Excellence Programme. The work of SSh, YT and YA were supported by the Federal Agency of Scientific Organizations via the Institute of Cytology and Genetics (project #0324-2019-0040). The work of LK was supported by the RCUK Innovation Fellowship from the National Productivity Investment Fund (MR/R026408/1). Karsten Suhre and Gaurav Thareja are supported by ‘Biomedical Research Program’ funds at Weill Cornell Medicine - Qatar, a program funded by the Qatar Foundation. We thank all staff at Weill Cornell Medicine - Qatar and Hamad Medical Corporation, and especially all study participants who made the QMDiab study possible.The SOCCS study was supported by grants from Cancer Research UK (C348/A3758, C348/A8896, C348/ A18927); Scottish Government Chief Scientist Office (K/OPR/2/2/D333, CZB/4/94); Medical Research Council (G0000657-53203, MR/K018647/1); Centre Grant from CORE as part of the Digestive Cancer Campaign (http://www.corecharity.org.uk). TwinsUK is funded by the Wellcome Trust, Medical Research Council, European Union, the National Institute for Health Research (NIHR)-funded BioResource, Clinical Research Facility and Biomedical Research Centre based at Guy’s and St Thomas’ NHS Foundation Trust in partnership with King’s College London. References: 1. Ohtsubo, K. & Marth, J. D. Glycosylation in Cellular Mechanisms of Health and Disease. Cell 126, 855–867 (2006). 2. Skropeta, D. The effect of individual N-glycans on enzyme activity. Bioorg. Med. Chem. 17, 2645–2653 (2009). 3. Takeuchi, H. et al. O-Glycosylation modulates the stability of epidermal growth factor-like repeats and thereby regulates Notch trafficking. J. Biol. Chem. 292, 15964–15973 (2017). 4. Lauc, G., Pezer, M., Rudan, I. & Campbell, H. Mechanisms of disease: The human N-glycome. Biochim. Biophys. Acta 1860, 1574–1582 (2015). 5. Poole, J., Day, C. J., von Itzstein, M., Paton, J. C. & Jennings, M. P. Glycointeractions in bacterial pathogenesis. Nat. Rev. Microbiol. 16, 440–452 (2018). 6. Lemmers, R. F. H. et al. IgG glycan patterns are associated with type 2 diabetes in independent European populations. Biochim. Biophys. Acta - Gen. Subj. 1861, 2240–2249 (2017). 7. Gudelj, I. et al. Low galactosylation of IgG associates with higher risk for future diagnosis of rheumatoid arthritis during 10 years of follow-up. Biochim. Biophys. Acta - Mol. Basis Dis. 1864, 2034–2039 (2018). 8. Russell, A. C. et al. The N-glycosylation of immunoglobulin G as a novel biomarker of Parkinson’s disease. Glycobiology 27, 501–510 (2017). 9. Vajaria, B. N. & Patel, P. S. Glycosylation: a hallmark of cancer? Glycoconj. J. 34, 147–156 (2017). 10. Munkley, J. & Elliott, D. J. Hallmarks of glycosylation in cancer. Oncotarget 7, 35478–35489 (2016). 11. Taniguchi, N. & Kizuka, Y. Glycans and cancer: role of N-glycans in cancer biomarker, progression and metastasis, and therapeutics. Adv. Cancer Res. 126, 11–51 (2015). 12. RodrÍguez, E., Schetters, S. T. T. & van Kooyk, Y. The tumour glyco-code as a novel immune checkpoint for immunotherapy. Nat. Rev. Immunol. 18, 204–211 (2018). 13. Thanabalasingham, G. et al. Mutations in HNF1A result in marked alterations of plasma glycan profile. Diabetes 62, 1329–1337 (2013). 14. Adamczyk, B., Tharmalingam, T. & Rudd, P. M. Glycans as cancer biomarkers. Biochim. Biophys. Acta - Gen. Subj. 1820, 1347–1353 (2012). 15. Shinohara, Y., Furukawa, J. & Miura, Y. in General Methods
Load more

Recommended publications
  • Molecular Mechanisms Involved Involved in the Interaction Effects of HCV and Ethanol on Liver Cirrhosis
    Virginia Commonwealth University VCU Scholars Compass Theses and Dissertations Graduate School 2010 Molecular Mechanisms Involved Involved in the Interaction Effects of HCV and Ethanol on Liver Cirrhosis Ryan Fassnacht Virginia Commonwealth University Follow this and additional works at: https://scholarscompass.vcu.edu/etd Part of the Physiology Commons © The Author Downloaded from https://scholarscompass.vcu.edu/etd/2246 This Thesis is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact [email protected]. Ryan C. Fassnacht 2010 All Rights Reserved Molecular Mechanisms Involved in the Interaction Effects of HCV and Ethanol on Liver Cirrhosis A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science at Virginia Commonwealth University. by Ryan Christopher Fassnacht, B.S. Hampden Sydney University, 2005 M.S. Virginia Commonwealth University, 2010 Director: Valeria Mas, Ph.D., Associate Professor of Surgery and Pathology Division of Transplant Department of Surgery Virginia Commonwealth University Richmond, Virginia July 9, 2010 Acknowledgement The Author wishes to thank his family and close friends for their support. He would also like to thank the members of the molecular transplant team for their help and advice. This project would not have been possible with out the help of Dr. Valeria Mas and her endearing
    [Show full text]
  • Selectin Ligand Sialyl-Lewis X Antigen Drives Metastasis of Hormone-Dependent Breast Cancers
    Published OnlineFirst October 24, 2011; DOI: 10.1158/0008-5472.CAN-11-1139 Cancer Tumor and Stem Cell Biology Research Selectin Ligand Sialyl-Lewis x Antigen Drives Metastasis of Hormone-Dependent Breast Cancers Sylvain Julien1, Aleksandar Ivetic2, Anita Grigoriadis3, Ding QiZe1, Brian Burford1, Daisy Sproviero1, Gianfranco Picco1, Cheryl Gillett4, Suzanne L. Papp5, Lana Schaffer5, Andrew Tutt3, Joyce Taylor-Papadimitriou1, Sarah E. Pinder4, and Joy M. Burchell1 Abstract The glycome acts as an essential interface between cells and the surrounding microenvironment. However, changes in glycosylation occur in nearly all breast cancers, which can alter this interaction. Here, we report that profiles of glycosylation vary between ER-positive and ER-negative breast cancers. We found that genes involved in the synthesis of sialyl-Lewis x (sLex; FUT3, FUT4, and ST3GAL6) are significantly increased in estrogen receptor alpha-negative (ER-negative) tumors compared with ER-positive ones. SLex expression had no influence on the survival of patients whether they had ER-negative or ER-positive tumors. However, high expression of sLex in ER- positive tumors was correlated with metastasis to the bone where sLex receptor E-selectin is constitutively expressed. The ER-positive ZR-75-1 and the ER-negative BT20 cell lines both express sLex but only ZR-75-1 cells could adhere to activated endothelial cells under dynamic flow conditions in a sLex and E-selectin–dependent manner. Moreover, L/P-selectins bound strongly to ER-negative MDA-MB-231 and BT-20 cell lines in a heparan sulfate (HS)–dependent manner that was independent of sLex expression. Expression of glycosylation genes involved in heparan biosynthesis (EXT1 and HS3ST1) was increased in ER-negative tumors.
    [Show full text]
  • Integrated Metabolomics and Proteomics Highlight Altered
    Carcinogenesis, 2017, Vol. 38, No. 3, 271–280 doi:10.1093/carcin/bgw205 Advance Access publication January 3, 2017 Original Manuscript original manuscript Integrated metabolomics and proteomics highlight altered nicotinamide and polyamine pathways in lung adenocarcinoma Johannes F.Fahrmann1,†, Dmitry Grapov2,†, Kwanjeera Wanichthanarak1, Brian C.DeFelice1, Michelle R.Salemi3, William N.Rom4, David R.Gandara5, Brett S.Phinney3, Oliver Fiehn1,6, Harvey Pass7 and Suzanne Miyamoto5,* 1University of California, Davis, West Coast Metabolomics Center, Davis, CA, USA, 2CDS Creative Data Solutions, Ballwin, MO, USA, 3Genome Center Proteomics Core Facility, UC Davis, Davis CA, USA 4Division of Pulmonary, Critical Care, and Sleep, NYU School of Medicine, New York, NY, USA, 5Division of Hematology and Oncology, Department of Internal Medicine, School of Medicine, University of California, Davis Medical Center, Sacramento, CA, USA, 6Department of Biochemistry, Faculty of Sciences, King Abdulaziz University, Jeddah, Saudi-Arabia, 7Division of Thoracic Surgery, Department of Cardiothoracic Surgery, Langone Medical Center, New York University, New York, NY, USA *To whom correspondence should be addressed. Tel: 916-734-3769; Email: [email protected] †-These authors contributed equally to this work. Abstract Lung cancer is the leading cause of cancer mortality in the United States with non-small cell lung cancer adenocarcinoma being the most common histological type. Early perturbations in cellular metabolism are a hallmark of cancer, but the extent of these changes in early stage lung adenocarcinoma remains largely unknown. In the current study, an integrated metabolomics and proteomics approach was utilized to characterize the biochemical and molecular alterations between malignant and matched control tissue from 27 subjects diagnosed with early stage lung adenocarcinoma.
    [Show full text]
  • Detecting Substrate Glycans of Fucosyltransferases on Glycoproteins with Fluorescent Fucose
    bioRxiv preprint doi: https://doi.org/10.1101/2020.01.28.919860; this version posted January 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Detecting substrate glycans of fucosyltransferases on glycoproteins with fluorescent fucose Key words: Fucose/Fucosylation/fucosyltransferase/core-fucose/glycosylation Supplementary Data Included: Supplemental Fig.1 to Fig. 2 Zhengliang L Wu1*, Mark Whitaker, Anthony D Person1, Vassili Kalabokis1 1Bio-techne, R&D Systems, Inc. 614 McKinley Place N.E. Minneapolis, MN, 55413, USA *Correspondence: Phone: 612-656-4544. Email: [email protected], bioRxiv preprint doi: https://doi.org/10.1101/2020.01.28.919860; this version posted January 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Abstract Like sialylation, fucose usually locates at the non-reducing ends of various glycans on glycoproteins and constitutes important glycan epitopes. Detecting the substrate glycans of fucosyltransferases is important for understanding how these glycan epitopes are regulated in response to different growth conditions and external stimuli. Here we report the detection of these glycans via enzymatic incorporation of fluorescent tagged fucose using fucosyltransferases including FUT2, FUT6, FUT7, and FUT8 and FUT9. More specifically, we describe the detection of substrate glycans of FUT8 and FUT9 on therapeutic antibodies and the detection of high mannose glycans on glycoproteins by enzymatic conversion of high mannose glycans to the substrate glycans of FUT8.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2003/0082511 A1 Brown Et Al
    US 20030082511A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0082511 A1 Brown et al. (43) Pub. Date: May 1, 2003 (54) IDENTIFICATION OF MODULATORY Publication Classification MOLECULES USING INDUCIBLE PROMOTERS (51) Int. Cl." ............................... C12O 1/00; C12O 1/68 (52) U.S. Cl. ..................................................... 435/4; 435/6 (76) Inventors: Steven J. Brown, San Diego, CA (US); Damien J. Dunnington, San Diego, CA (US); Imran Clark, San Diego, CA (57) ABSTRACT (US) Correspondence Address: Methods for identifying an ion channel modulator, a target David B. Waller & Associates membrane receptor modulator molecule, and other modula 5677 Oberlin Drive tory molecules are disclosed, as well as cells and vectors for Suit 214 use in those methods. A polynucleotide encoding target is San Diego, CA 92121 (US) provided in a cell under control of an inducible promoter, and candidate modulatory molecules are contacted with the (21) Appl. No.: 09/965,201 cell after induction of the promoter to ascertain whether a change in a measurable physiological parameter occurs as a (22) Filed: Sep. 25, 2001 result of the candidate modulatory molecule. Patent Application Publication May 1, 2003 Sheet 1 of 8 US 2003/0082511 A1 KCNC1 cDNA F.G. 1 Patent Application Publication May 1, 2003 Sheet 2 of 8 US 2003/0082511 A1 49 - -9 G C EH H EH N t R M h so as se W M M MP N FIG.2 Patent Application Publication May 1, 2003 Sheet 3 of 8 US 2003/0082511 A1 FG. 3 Patent Application Publication May 1, 2003 Sheet 4 of 8 US 2003/0082511 A1 KCNC1 ITREXCHO KC 150 mM KC 2000000 so 100 mM induced Uninduced Steady state O 100 200 300 400 500 600 700 Time (seconds) FIG.
    [Show full text]
  • Glycosylation of Igg Associates with Hypertension and Type 2 Diabetes Mellitus Comorbidity in the Chinese Muslim Ethnic Minorities and the Han Chinese
    Journal of Personalized Medicine Article Glycosylation of IgG Associates with Hypertension and Type 2 Diabetes Mellitus Comorbidity in the Chinese Muslim Ethnic Minorities and the Han Chinese Xiaoni Meng 1 , Manshu Song 1,2,* , Marija Vilaj 3, Jerko Štambuk 3, Mamatyusupu Dolikun 4, Jie Zhang 1, Di Liu 1, Hao Wang 5 , Xiaoyu Zhang 1, Jinxia Zhang 1, Weijie Cao 1, Ana Momˇcilovi´c 3, Irena Trbojevi´c-Akmaˇci´c 3 , Xingang Li 2,6 , Deqiang Zheng 1, Lijuan Wu 1, Xiuhua Guo 1, Youxin Wang 1,2 , Gordan Lauc 3,7 and Wei Wang 1,2,6 1 Beijing Key Laboratory of Clinical Epidemiology, School of Public Health, Capital Medical University, Beijing 100069, China; [email protected] (X.M.); [email protected] (J.Z.); [email protected] (D.L.); [email protected] (X.Z.); [email protected] (J.Z.); [email protected] (W.C.); [email protected] (D.Z.); [email protected] (L.W.); [email protected] (X.G.); [email protected] (Y.W.); [email protected] (W.W.) 2 School of Medical and Health Sciences, Edith Cowan University, Perth, WA 6027, Australia; [email protected] 3 Genos Glycoscience Research Laboratory, 10000 Zagreb, Croatia; [email protected] (M.V.); [email protected] (J.Š.); [email protected] (A.M.); [email protected] (I.T.-A.); [email protected] (G.L.) 4 College of the Life Sciences and Technology, Xinjiang University, Urumqi 830046, China; [email protected] Citation: Meng, X.; Song, M.; Vilaj, 5 Department of Clinical Epidemiology and Evidence-Based Medicine, M.; Štambuk, J.; Dolikun, M.; Zhang, National Clinical Research Center for Digestive Disease, Beijing Friendship Hospital, J.; Liu, D.; Wang, H.; Zhang, X.; Capital Medical University, Beijing 100050, China; [email protected] Zhang, J.; et al.
    [Show full text]
  • CDG and Immune Response: from Bedside to Bench and Back Authors
    CDG and immune response: From bedside to bench and back 1,2,3 1,2,3,* 2,3 1,2 Authors: Carlota Pascoal , Rita Francisco , Tiago Ferro , Vanessa dos Reis Ferreira , Jaak Jaeken2,4, Paula A. Videira1,2,3 *The authors equally contributed to this work. 1 Portuguese Association for CDG, Lisboa, Portugal 2 CDG & Allies – Professionals and Patient Associations International Network (CDG & Allies – PPAIN), Caparica, Portugal 3 UCIBIO, Departamento Ciências da Vida, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, 2829-516 Caparica, Portugal 4 Center for Metabolic Diseases, UZ and KU Leuven, Leuven, Belgium Word count: 7478 Number of figures: 2 Number of tables: 3 This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/jimd.12126 This article is protected by copyright. All rights reserved. Abstract Glycosylation is an essential biological process that adds structural and functional diversity to cells and molecules, participating in physiological processes such as immunity. The immune response is driven and modulated by protein-attached glycans that mediate cell-cell interactions, pathogen recognition and cell activation. Therefore, abnormal glycosylation can be associated with deranged immune responses. Within human diseases presenting immunological defects are Congenital Disorders of Glycosylation (CDG), a family of around 130 rare and complex genetic diseases. In this review, we have identified 23 CDG with immunological involvement, characterised by an increased propensity to – often life-threatening – infection.
    [Show full text]
  • Cartilage Oligomeric Matrix Protein (COMP)-Mediated Cell Differentiation to Proteolysis Mechanism Networks from Human Normal Adjacent Tissues to Lung Adenocarcinoma
    Analytical Cellular Pathology 36 (2013) 93–105 93 DOI 10.3233/ACP-130084 IOS Press Cartilage oligomeric matrix protein (COMP)-mediated cell differentiation to proteolysis mechanism networks from human normal adjacent tissues to lung adenocarcinoma Lin Wanga,b,∗, Juxiang Huanga,1, Minghu Jiangc,1, Haizhen Diaoa, Huilei Zhoua, Xiaohe Lia, Qingchun Chena, Zhenfu Jiangd, Haitao Fenge and Stefan Wolflf aBioinformatics Center, School of Electronic Engineering, Beijing University of Posts and Telecommunications, Beijing, China bState key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China cLab of Computational Linguistics, School of Humanities and Social Sciences, Tsinghua University, Beijing, China dSchool of Mechanical Electronic & Information Engineering, China University of Mining & Technology, Beijing, China eDean department, Heilongjiang University of Chinese Medicine, Harbin, China f Institute of Pharmacy and Molecular Biotechnology, Heidelberg University, Heidelberg, Germany Abstract. BACKGROUND: To understand cartilage oligomeric matrix protein (COMP) mechanism network from human normal adjacent tissues to lung adenocarcinoma. METHODS: COMP complete different activated (all no positive correlation, Pearson CC < 0.25) and uncomplete (partly no positive correlation except COMP, Pearson CC < 0.25) network were identified in higher lung adenocarcinoma compared with lower human normal adjacent tissues from the corresponding COMP-stimulated (≥0.25) or inhibited (Pearson CC ≤−0.25) overlapping
    [Show full text]
  • Glycan Metabolism a Validated Grna Library for CRISPR/Cas9
    Glycobiology, 2018, vol. 28, no. 5, 295–305 doi: 10.1093/glycob/cwx101 Advance Access Publication Date: 5 January 2018 Original Article Glycan Metabolism A validated gRNA library for CRISPR/Cas9 targeting of the human glycosyltransferase Downloaded from https://academic.oup.com/glycob/article-abstract/28/5/295/4791732 by guest on 08 October 2018 genome Yoshiki Narimatsu2,3,1, Hiren J Joshi2, Zhang Yang2,3, Catarina Gomes2,4, Yen-Hsi Chen2, Flaminia C Lorenzetti 2, Sanae Furukawa2, Katrine T Schjoldager2, Lars Hansen2, Henrik Clausen2, Eric P Bennett2,1, and Hans H Wandall2 2Copenhagen Center for Glycomics, Departments of Cellular and Molecular Medicine and Odontology, Faculty of Health Sciences, University of Copenhagen, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark, 3GlycoDisplay Aps, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark, and 4Instituto de Investigação e Inovação em Saúde,i3S; Institute of Molecular Pathology and Immunology of University of Porto, Ipatimup, Rua Júlio Amaral de Carvalho, 45, Porto 4200-135, Portugal 1To whom correspondence should be addressed: Tel: +45-35335528; Fax: +45-35367980; e-mail: [email protected] (Y.N.); Tel: +4535326630; Fax: +45-35367980; e-mail: [email protected] (E.P.B.) Received 25 September 2017; Revised 20 November 2017; Editorial decision 5 December 2017; Accepted 7 December 2017 Abstract Over 200 glycosyltransferases are involved in the orchestration of the biosynthesis of the human glycome, which is comprised of all glycan structures found on different glycoconjugates in cells. The glycome is vast, and despite advancements in analytic strategies it continues to be difficult to decipher biological roles of glycans with respect to specific glycan structures, type of glycoconju- gate, particular glycoproteins, and distinct glycosites on proteins.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2003/0198970 A1 Roberts (43) Pub
    US 2003O19897OA1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0198970 A1 Roberts (43) Pub. Date: Oct. 23, 2003 (54) GENOSTICS clinical trials on groups or cohorts of patients. This group data is used to derive a Standardised method of treatment (75) Inventor: Gareth Wyn Roberts, Cambs (GB) which is Subsequently applied on an individual basis. There is considerable evidence that a significant factor underlying Correspondence Address: the individual variability in response to disease, therapy and FINNEGAN, HENDERSON, FARABOW, prognosis lies in a person's genetic make-up. There have GARRETT & DUNNER been numerous examples relating that polymorphisms LLP within a given gene can alter the functionality of the protein 1300 ISTREET, NW encoded by that gene thus leading to a variable physiological WASHINGTON, DC 20005 (US) response. In order to bring about the integration of genomics into medical practice and enable design and building of a (73) Assignee: GENOSTIC PHARMA LIMITED technology platform which will enable the everyday practice (21) Appl. No.: 10/206,568 of molecular medicine a way must be invented for the DNA Sequence data to be aligned with the identification of genes (22) Filed: Jul. 29, 2002 central to the induction, development, progression and out come of disease or physiological States of interest. Accord Related U.S. Application Data ing to the invention, the number of genes and their configu rations (mutations and polymorphisms) needed to be (63) Continuation of application No. 09/325,123, filed on identified in order to provide critical clinical information Jun. 3, 1999, now abandoned. concerning individual prognosis is considerably less than the 100,000 thought to comprise the human genome.
    [Show full text]
  • Multiplexed Surrogate Analysis of Glycotransferase Activity in Whole Biospecimens † † ‡ Chad R
    Article pubs.acs.org/ac Multiplexed Surrogate Analysis of Glycotransferase Activity in Whole Biospecimens † † ‡ Chad R. Borges, ,* Douglas S. Rehder, and Paolo Boffetta † Molecular Biomarkers Unit, The Biodesign Institute at Arizona State University, Tempe, Arizona 85287, United States ‡ Institute for Translational Epidemiology and Tisch Cancer Institute, Mount Sinai School of Medicine, New York, New York 10029, United States *S Supporting Information ABSTRACT: Dysregulated glycotransferase enzymes in can- cer cells produce aberrant glycanssome of which can help facilitate metastases. Within a cell, individual glycotransferases promiscuously help to construct dozens of unique glycan structures, making it difficult to comprehensively track their activity in biospecimensespecially where they are absent or inactive. Here, we describe an approach to deconstruct glycans in whole biospecimens then analytically pool together resulting monosaccharide-and-linkage-specific degradation products (“glycan nodes”) that directly represent the activities of specific glycotransferases. To implement this concept, a reproducible, relative quantitation-based glycan methylation analysis methodology was developed that simultaneously captures information from N-, O-, and lipid linked glycans and is compatible with whole biofluids and homogenized tissues; in total, over 30 different glycan nodes are detectable per gas chromatography−mass spectrometry (GC-MS) run. Numerous nonliver organ cancers are known to induce the production of abnormally glycosylated serum proteins. Thus, following analytical validation, in blood plasma, the technique was applied to a group of 59 lung cancer patient plasma samples and age/gender/ smoking-status-matched non-neoplastic controls from the Lung Cancer in Central and Eastern Europe (CEE) study to gauge the clinical utility of the approach toward the detection of lung cancer.
    [Show full text]